Seagen

Seagen Inc. is a biotechnology company, which engages in the development and commercialization of antibody-based therapies for the treatment of cancer. Its products include Adcetris and Padcev. The firm is also advancing a pipeline of novel therapies for solid tumors and blood-related cancers. The company was founded by Clay B. Siegall and H. Perry Fell on July 15, 1997, and is headquartered in Bothell, WA.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q3 2024

Seagen reports robust Q4 earnings, poised for growth and innovation

Seagen's strong financial performance, focus on key products like ADCETRIS and PADCEV, and strategic investments in R&D position the company for continued growth.
While facing challenges in managing expenses and navigating competitive markets, Seagen's commitment to innovation and pipeline development presents opportunities for future success.
Overall, Seagen's performance in Q4 2022 reflects a company poised for growth, with a clear strategic focus on optimizing its commercial portfolio and advancing clinical programs.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Seattle Genetics is a clinical-stage biotechnology company that focuses on developing and commercializing monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases. Its lead product, SGN-35, is in the pivotal trial for patients with relapsed or refractory Hodgkin lymphoma. The company's other product candidates in various stages of clinical trials include dacetuzumab (SGN-40), a humanized anti-CD40 antibody; lintuzumab (SGN-33), a humanized anti-CD33 antibody; SGN-70, a humanized anti-CD70 antibody for the treatment of autoimmune diseases; SGN-75, which is in Phase I clinical trials for metastatic renal cell carcinoma and non-Hodgkin lymphoma; ASG-5ME, a preclinical antibody-drug conjugate product candidate for the treatment of solid tumors; and SGN-19A, a preclinical antibody-drug conjugate product candidate for the treatment of hematologic malignancies. It has collaborations with Bayer Pharmaceuticals Corporation; Celldex Therapeutics, Inc.; Daiichi Sankyo Co., Ltd.; Genentech; GlaxoSmithKline LLC; MedImmune, Inc.; Millennium; PSMA Development Company LLC; and Genmab A/S. The company also has an antibody-drug conjugates co-development agreement with Agensys, Inc.  The company was founded in 1997 and is headquartered in Bothell, Washington.

BOTHELL, Wash.--(BUSINESS WIRE)--Seattle Genetics, Inc.

Seattle Genetics Highlights Data from Broad Oncology Portfolio During ESMO Virtual Congress 2020

Seattle Genetics Appoints Ted W. Love, M.D.

Seattle Genetics Announces TUKYSA® (tucatinib) Approved Within Months for All Countries Participating in FDA’s Project Orbis Initiative

Seattle Genetics Achieves Milestone Payment Under Antibody-Drug Conjugate Collaboration with GlaxoSmithKline Triggered by BLENREP (belantamab mafodotin-blmf) FDA Approval

Seattle Genetics (SGEN) reports a narrower-than-expected loss and beats sales estimates in the second quarter of 2020.

Seattle Genetics (SGEN) Q2 Earnings Beat, Adcetris Aids Sales

Seattle Genetics, Inc. (SGEN) CEO Clay Siegall on Q2 2020 Results - Earnings Call Transcript

Seattle Genetics Reports Second Quarter 2020 Financial Results

Seattle Genetics is a biotechnology R&D company with a robust business model. The company’s primary focus is on developing cancer drugs using antibody–drug conjugate (ADC) technology.

Seattle Genetics: Profitable Products, Exciting Pipeline

Bunge Global SA

CACI

Edgewell Personal Care

NRG Energy

With 2020 already more than half over and the third quarter in full swing, many investors are resetting for what could be a more volatile rest of the year.

5 Goldman Sachs Conviction Buy Stocks With the Most Upside

Seattle Genetics, Inc’s (NASDAQ: SGEN) stock already reflects the urothelial bladder cancer opportunity, according to Piper Sandler.

Piper Sandler Downgrades Seattle Genetics, Says Visibility Limited On Value Creation

Amgen

BioMarin Pharmaceutical

Eli Lilly

Regeneron Pharmaceuticals

Vertex Pharmaceuticals

Zoetis

The health care sector has been a big winner in 2020, far outpacing the Dow Jones industrial average and S&P 500.

Goldman Sachs Sees Big Gains From 7 Biotech & Pharma Conviction Buy Stocks

BOTHELL, Wash.--(BUSINESS WIRE)--Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will report its second quarter 2020 financial results on Thursday, July 30, 2020 after the close of financial markets. Following the announcement, Company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows: Thursday, July 30, 2020 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time Telephone 86

Seattle Genetics to Host Conference Call and Webcast Discussion of Second Quarter 2020 Financial Results on July 30, 2020

Seattle Genetics (SEGN) focuses on improving sales of its flagship product, Adcetris. Further, label expansions of the drug should continue to boost the top line.

Seattle Genetics' Adcetris Progresses Well Amid Competition

Two drug approvals in just a few months gave investors reason to cheer.

Why Seattle Genetics Shares Climbed 48.7% in the First Half

DexCom

Teladoc

West Pharmaceutical Services

Teladoc Health, Dexcom, Vertex Pharmaceuticals, Seattle Genetics and West Pharmaceutical Services are medical stocks in or near buy zones.
The post Teladoc, Dexcom, Vertex, Seattle Genetics, West Pharmaceutical: Five Medical Stocks In Or Near Buy Zones appeared first on Investor's Business Daily.

Teladoc, Dexcom, Vertex, Seattle Genetics, West Pharmaceutical: Five Medical Stocks In Or Near Buy Zones

BOTHELL, Wash.--(BUSINESS WIRE)--Seattle Genetics, Inc. (Nasdaq:SGEN) today announced positive topline results from the phase 2 single-arm clinical trial known as innovaTV 204 evaluating tisotumab vedotin administered every three weeks for the treatment of patients who have relapsed or progressed on or after prior treatment for recurrent or metastatic cervical cancer. Results from the trial showed a 24 percent confirmed objective response rate (ORR) by independent central review [95% Confidence

Seattle Genetics Announces Positive Topline Results from Phase 2 Clinical Trial of Tisotumab Vedotin in Recurrent or Metastatic Cervical Cancer

Exelixis

Gilead Sciences

These companies have products, products, and more products to keep revenue flowing.

3 Biotech Stocks I’d Buy Right Now

Incyte

Lam Research

Zoom Video

In a tug of war between bulls and bears, the Dow Jones and S&P 500 gained at least 1% each last week while the Nasdaq Composite Index advanced over 3%.

Nasdaq's Excels in Weekly Performance: 5 Best Stocks in ETF

Seattle Genetics (SGEN) reported earnings 30 days ago. What's next for the stock?

Why Is Seattle Genetics (SGEN) Up 14.6% Since Last Earnings Report?

Seattle Genetics (SGEN) secures a nod from the European Commission for Adcetris to treat adult patients with previously untreated systemic anaplastic large cell lymphoma.

Seattle Genetics' Adcetris Label Expands in EU for Lymphoma

Even though it’s not expected to be profitable until 2022, Seattle Genetics Inc.

Analysts See Seattle Genetics Profitable in 2022

Seattle Genetics (SGEN) reports narrower-than-expected loss in Q1 while revenues beat estimates.

Seattle Genetics (SGEN) Q1 Earnings Beat, Adcetris Aids Sales

Seattle Genetics' (SGEN) CEO Clay Siegall on Q1 2020 Results - Earnings Call Transcript

As of late, it has definitely been a great time to be an investor Seattle Genetics

Will Seattle Genetics Continue to Surge Higher?

In what has become truly the most challenging investing environment in decades, it is probably no surprise to most investors that health care is the top-performing sector this year in the S&P 500.

Goldman Sachs Says Buy 4 Biotech Stocks in Front of Q1 Earnings

News for Seagen Stock (SGEN)